Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function
- PMID: 21433043
- DOI: 10.1002/hep.24315
Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function
Abstract
Clinical studies of bone marrow (BM) cell therapy for liver cirrhosis are under way but the mechanisms of benefit remain undefined. Cells of the monocyte-macrophage lineage have key roles in the development and resolution of liver fibrosis. Therefore, we tested the therapeutic effects of these cells on murine liver fibrosis. Advanced liver fibrosis was induced in female mice by chronic administration of carbon tetrachloride. Unmanipulated, syngeneic macrophages, their specific BM precursors, or unfractionated BM cells were delivered during liver injury. Mediators of inflammation, fibrosis, and regeneration were measured. Donor cells were tracked by sex-mismatch and green fluorescent protein expression. BM-derived macrophage (BMM) delivery resulted in early chemokine up-regulation with hepatic recruitment of endogenous macrophages and neutrophils. These cells delivered matrix metalloproteinases-13 and -9, respectively, into the hepatic scar. The effector cell infiltrate was accompanied by increased levels of the antiinflammatory cytokine interleukin 10. A reduction in hepatic myofibroblasts was followed by reduced fibrosis detected 4 weeks after macrophage infusion. Serum albumin levels were elevated at this time. Up- regulation of the liver progenitor cell mitogen tumor necrosis factor-like weak inducer of apoptosis (TWEAK) preceded expansion of the progenitor cell compartment. Increased expression of colony stimulating factor-1, insulin-like growth factor-1, and vascular endothelial growth factor also followed BMM delivery. In contrast to the effects of differentiated macrophages, liver fibrosis was not significantly altered by the application of macrophage precursors and was exacerbated by whole BM.
Conclusion: Macrophage cell therapy improves clinically relevant parameters in experimental chronic liver injury. Paracrine signaling to endogenous cells amplifies the effect. The benefits from this single, defined cell type suggest clinical potential.
Copyright © 2011 American Association for the Study of Liver Diseases.
Comment in
-
Stem cells or macrophages: which contribute to bone marrow cell therapy for liver cirrhosis?Hepatology. 2011 Sep 2;54(3):1103; author reply 1104. doi: 10.1002/hep.24431. Epub 2011 Jul 25. Hepatology. 2011. PMID: 21607998 No abstract available.
Similar articles
-
Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice.J Hepatol. 2017 Oct;67(4):770-779. doi: 10.1016/j.jhep.2017.05.022. Epub 2017 Jul 26. J Hepatol. 2017. PMID: 28596109
-
Stem cells or macrophages: which contribute to bone marrow cell therapy for liver cirrhosis?Hepatology. 2011 Sep 2;54(3):1103; author reply 1104. doi: 10.1002/hep.24431. Epub 2011 Jul 25. Hepatology. 2011. PMID: 21607998 No abstract available.
-
Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model.Am J Pathol. 2016 Mar;186(3):524-38. doi: 10.1016/j.ajpath.2015.10.029. Epub 2016 Jan 4. Am J Pathol. 2016. PMID: 26762581
-
Status of and candidates for cell therapy in liver cirrhosis: overcoming the "point of no return" in advanced liver cirrhosis.J Gastroenterol. 2017 Feb;52(2):129-140. doi: 10.1007/s00535-016-1258-1. Epub 2016 Sep 8. J Gastroenterol. 2017. PMID: 27631592 Review.
-
Macrophage heterogeneity in liver injury and fibrosis.J Hepatol. 2014 May;60(5):1090-6. doi: 10.1016/j.jhep.2013.12.025. Epub 2014 Jan 8. J Hepatol. 2014. PMID: 24412603 Review.
Cited by
-
Modulating macrophage activities to promote endogenous bone regeneration: Biological mechanisms and engineering approaches.Bioact Mater. 2020 Aug 22;6(1):244-261. doi: 10.1016/j.bioactmat.2020.08.012. eCollection 2021 Jan. Bioact Mater. 2020. PMID: 32913932 Free PMC article. Review.
-
Immune cell-mediated features of non-alcoholic steatohepatitis.Nat Rev Immunol. 2022 Jul;22(7):429-443. doi: 10.1038/s41577-021-00639-3. Epub 2021 Nov 5. Nat Rev Immunol. 2022. PMID: 34741169 Free PMC article. Review.
-
Neutrophils alleviate fibrosis in the CCl4-induced mouse chronic liver injury model.Hepatol Commun. 2018 Apr 12;2(6):703-717. doi: 10.1002/hep4.1178. eCollection 2018 Jun. Hepatol Commun. 2018. PMID: 29881822 Free PMC article.
-
Platelet-rich plasma-derived extracellular vesicles improve liver cirrhosis in mice.Regen Ther. 2024 Nov 6;26:1048-1057. doi: 10.1016/j.reth.2024.10.010. eCollection 2024 Jun. Regen Ther. 2024. PMID: 39569343 Free PMC article.
-
Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies.Cell Mol Immunol. 2016 May;13(3):316-27. doi: 10.1038/cmi.2015.104. Epub 2016 Feb 24. Cell Mol Immunol. 2016. PMID: 26908374 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials